M.d. Anderson Cancer Center

This study tested a combination of three drugs (panitumumab, carboplatin, and paclitaxel) given before surgery to women with triple-negative breast cancer that did not respond to standard chemotherapy. The goal was to shrink tumors enough to allow less extensive surgery. The tria…

This study tested a new treatment for people with certain types of lymphoma (Hodgkin or non-Hodgkin) that returned or didn't respond to standard therapy. The treatment combines a special antibody (AFM13) with immune cells called natural killer (NK) cells from donated umbilical co…

This study tested a combination of the immunotherapy drug pembrolizumab and targeted radiation in 17 patients with non-Hodgkin lymphoma that had returned or stopped responding to treatment. The goal was to see if adding radiation could help the immune system fight the cancer bett…

This early-phase trial tested a combination of two drugs—binimetinib and hydroxychloroquine—in 34 people with advanced pancreatic cancer that has a specific gene change (KRAS mutation) and has spread to other parts of the body. The goal was to find the safest dose of hydroxychlor…

This study looked at whether adding the drug axitinib to standard hormone therapy before surgery could help control prostate cancer that had spread to lymph nodes. 73 men with previously untreated prostate cancer took part. The goal was to see if the combination delayed cancer pr…

This study looked at whether adding the targeted drug erlotinib to standard chemotherapy (docetaxel plus cisplatin or carboplatin) helps shrink head and neck tumors more than chemo alone before surgery. About 55 adults with advanced but operable head and neck cancer took part. Th…

This study tested a drug called sintilimab in 10 people with advanced cancer of unknown primary (CUP) that had not responded to standard chemotherapy. Sintilimab is an immunotherapy that helps the immune system attack cancer cells. The goal was to see if the drug could shrink tum…

This study looked at whether adding a special scope test (EBUS-TBNA) after a standard PET/CT scan can more accurately stage early-stage non-small cell lung cancer. About 150 patients with stage I-IIA cancer who were being considered for radiation therapy took part. The goal was t…

This study tested whether contrast-enhanced mammography (CEM) can find breast cancers that standard mammograms miss. 89 women already diagnosed or highly suspected of having breast cancer received CEM, which uses an iodine dye to make tumors stand out. The goal was to see if CEM …